Market Research Logo

The Global Ophthalmic Drugs Market

The Global Ophthalmic Drugs Market

Ophthalmic Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast upto2024

Overview: Ophthalmic drugs are widely used for thetreatment of eye disorders bsuch as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drugdelivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currectly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinationsin eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in thedevelopment of combination drugs for the glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to opthalmic drugs andloss of patent for blockbuster drugs are hampering the market growth.

Market Analysis: The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis: In future, several blockbuster drugs that have dominated the morated, are expected to lose their patents. The patents of successful products accounted for over $6 billion. . Theloss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a german biosimilars developing companyis currently developing biosimilar for Eylea by Regeneron Pharmaceutical’s. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:


1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical Spending Region Wise
1.1.3 R&D Pipeline in Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017 ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.2.1 Trends in the Ophthalmic Drugs Market
3.3 Related Markets
3.3.1 Bacterial Conjunctivitis Drugs
3.3.1.1 Trends of Bacterial Conjunctivitis Drugs Market
3.3.2 Contact Lenses
3.3.2.1 Trends of contact lens market
4 Market Outline
4.1 Ophthalmic Drugs Approved by FDA
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of eye diseases
5.1.1.2 Increasing prevalence of cataract
5.1.1.3 Increasing aging population
5.1.2 Opportunities
5.1.2.1 Increasing mergers & acquisitions
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Loss of patent for blockbuster drugs
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Indication: Market Size and Analysis
6.1 Overview
6.2 Dry Eyes
6.3 Glaucoma
6.4 Eye Infection/ Inflammation
6.5 Retinal Disorder
6.6 Others
7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.3 Europe
7.3.1 Overview
7.4 Asia Pacific
7.4.1 Overview
7.5 Rest of the World
7.5.1 Overview
8 Competitive Landscape
9 Vendor Profiles
9.1 Allergan PLC
9.1.1 Overview
9.1.2 Business Units
9.1.3 Geographic Revenue
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategies
9.2 Novartis AG
9.2.1 Overview
9.2.2 Business Units
9.2.3 Geographic Presence
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategy
9.3 Pfizer Inc.
9.3.1 Overview
9.3.2 Business Units
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategies
9.4 Valeant Pharmaceuticals International Inc. (Bausch Health)
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategy
9.5 Santen Pharmaceutical Co., Ltd
9.5.1 Overview
9.5.2 Business Units
9.5.3 Geographic Presence
9.5.4 Business Focus
9.5.5 SWOT Analysis
9.5.6 Business Strategies
9.6 Akorn Inc.
9.6.1 Overview
9.6.2 Business Focus
9.6.3 SWOT Analysis
9.6.4 Business Strategy
9.7 Johnson & Johnson
9.7.1 Overview
9.7.2 Business Units
9.7.3 Geographic Revenue
9.7.4 Business Focus
9.7.5 SWOT Analysis
9.7.6 Business Strategies
10 Companies to Watch for
10.1 Shire plc
10.1.1 Overview
10.1.2 Highlights
10.2 Daiichi Sankyo, Inc.
10.2.1 Overview
10.2.2 Highlights
10.3 Bayer AG
10.3.1 Overview
10.4 F. Hoffmann-La Roche (Genentech)
10.4.1 Overview
10.5 Sun Pharmaceuticals
10.5.1 Overview
10.5.2 Highlights
Annexure
Abbreviations
Tables
TABLE 1 NOVARTIS AG: OFFERINGS
TABLE 2 NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 3 PFIZER INC.: OFFERINGS
TABLE 4 PFIZER INC.: RECENT DEVELOPMENTS
TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS
TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS
TABLE 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS
TABLE 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS
TABLE 9 AKORN INC: OFFERINGS
TABLE 10 AKORN INC.: RECENT DEVELOPMENTS
TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 13 SHIRE PLC: OVERVIEW
TABLE 14 SHIRE PLC: RECENT DEVELOPMENTS
TABLE 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS
TABLE 16 BAYER AG: OVERVIEW
TABLE 17 BAYER AG: RECENT DEVELOPMENTS
TABLE 18 F. HOFFMANN-LA ROCHE: OVERVIEW
TABLE 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
 "
Charts
CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2016)
CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
CHART 3 CAUSES OF SIGHT LOSS GLOBALLY
CHART 4 RESEARCH METHODOLOGY OF GLOBAL OPHTHALMIC DRUGS MARKET
CHART 5 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE, 2017-2024 ($MILLION)
CHART 6 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS
CHART 7 OPHTHALMIC DRUGS APPROVED BY FDA DURING 2011–2017
CHART 8 SEGMENTATION OF GLOBAL OPHTHALMIC DRUGS MARKET
CHART 9 PORTER 5 FORCES OF OPHTHALMIC DRUGS MARKET
CHART 10 PEST ANALYSIS OF OPHTHALMIC DRUGS MARKET
CHART 11 MARKET DYNAMICS – DRO ANALYSIS
CHART 12 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960–2060 (%)
CHART 13 DRO – IMPACT ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET
CHART 14 KEY STAKEHOLDERS
CHART 15 OPHTHALMIC DRUGS MARKET BY PRODUCTS TYPE SEGMENTATION, 2017-2024 ($MILLION)
CHART 16 OPHTHALMIC DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017–2024 ($MILLION)
CHART 17 DRY EYES DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION)
CHART 18 GLAUCOMA DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION)
CHART 19 EYE INFECTION/ INFLAMATION DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($MILLION)
CHART 20 RETINAL DISORDER DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION)
CHART 21 OTHERS OPHTHALMIC DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION)
CHART 22 OPHTHALMIC DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
CHART 23 OPHTHALMIC DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
CHART 24 OPHTHALMIC DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
CHART 25 OPHTHALMIC DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
CHART 26 OPHTHALMIC DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION)
CHART 27 OPHTHALMIC DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
CHART 28 ALLERGAN PLC: OFFERINGS
CHART 29 ALLERGAN PLC: RECENT DEVELOPMENTS
CHART 30 ALLERGAN PLC: OVERVIEW SNAPSHOT
CHART 31 ALLERGAN PLC: BUSINESS UNITS
CHART 32 ALLERGAN PLC: GEOGRAPHIC REVENUE
CHART 33 ALLERGAN PLC: SWOT ANALYSIS
CHART 34 NOVARTIS AG: OVERVIEW SNAPSHOT
CHART 35 NOVARTIS AG: BUSINESS UNITS
CHART 36 NOVARTIS AG: GEOGRAPHICAL PRESENCE
CHART 37 NOVARTIS AG: SWOT ANALYSIS
CHART 38 PFIZER INC.: OVERVIEW SNAPSHOT
CHART 39 PFIZER INC.: BUSINESS UNITS
CHART 40 PFIZER INC.: GEOGRAPHIC PRESENCE
CHART 41 PFIZER INC.: SWOT ANALYSIS
CHART 42 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OVERVIEW SNAPSHOT
CHART 43 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: BUSINESS UNITS
CHART 44 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE
CHART 45 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: SWOT ANALYSIS
CHART 46 SANTEN PHARMACEUTICAL CO., LTD: OVERVIEW SNAPSHOT
CHART 47 SANTEN PHARMACEUTICAL CO., LTD: BUSINESS UNITS
CHART 48 SANTEN PHARMACEUTICAL CO., LTD: GEOGRAPHIC PRESENCE
CHART 49 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS
CHART 50 AKORN INC.: OVERVIEW SNAPSHOT
CHART 51 AKORN INC.: BUSINESS UNITS
CHART 52 AKORN INC.: SWOT ANALYSIS
CHART 53 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 54 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 55 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 56 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 57 SUN PHARMACEUTICALS: OVERVIEW

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report